Abstract
Background: Putranjiva roxburghii Wall is traditionally known to cure many pathological conditions including epilepsy.
Objective: The present study is aimed at determining bioactive compounds in ethanolic extract of Putranjiva roxburghii test extract (PRTE) seeds by GCMS analysis and to assess its antiepileptic potential using various experimental models of epilepsy.
Methods: The ethanolic extract of seeds of Putranjiva roxburghii was subjected to GC-MS analysis to detect the bioactive phytoconstituents. Acute oral toxicity of the extract was performed using OCED guideline 420. Pentylenetetrazol (PTZ) kindling model of epilepsy and Maximal electroshock epilepsy (MES) model of epilepsy were used to determine anti-epileptic potential.
Results: The GC-MS analysis of the extract revealed the presence of 20 phytoconstituents. The major phytoconstituents included n-Propyl heptyl ether (25.25%), 5-Ethyl hydantoin (8%), octadec- 9-enoic acid (16.25%) and 1, 2-Benzene dicarboxylic acid (11.86%). The PRTE (50 mg/kg and 100 mg/kg) afforded a significant and dose-dependent protection against PTZ-induced kindling epilepsy and MES induced epilepsy (p<0.001 and p<0.01).
Conclusion: Based on the above findings, it is evident that Putranjiva roxburghii seeds contain biologically active compounds. It can also be concluded that the extract possesses anti-epileptic potential.
Keywords: GC-MS analysis, anti-epileptic activity, Putranjiva roxburghii, 5-Ethylhydantoin, PTZ – induced kindling epilepsy, MES induced epilepsy.
Graphical Abstract
[http://dx.doi.org/10.1007/978-0-387-70638-2]
[http://dx.doi.org/10.1007/s12010-011-9445-2] [PMID: 22086564]
[http://dx.doi.org/10.1155/2012/614046]
[http://dx.doi.org/10.1016/S0975-3575(10)80105-1]
[http://dx.doi.org/10.1016/j.dib.2018.04.124] [PMID: 29904686]
[http://dx.doi.org/10.1016/j.neurol.2015.11.003] [PMID: 26754036]
[http://dx.doi.org/10.1016/S2221-1691(12)60092-6] [PMID: 23569966]
[http://dx.doi.org/10.2176/nmc.ra.2015-0344] [PMID: 26935782]
[http://dx.doi.org/10.1016/j.epilep.2013.01.001]
[http://dx.doi.org/10.2174/156802612800229215] [PMID: 22352861]
[http://dx.doi.org/10.18632/oncotarget.16801] [PMID: 28423368]
[http://dx.doi.org/10.1007/s13197-013-1105-9] [PMID: 25694742]
[http://dx.doi.org/10.1016/j.phcgj.2013.09.005]
[http://dx.doi.org/10.5530/pj.2019.1.24]
[http://dx.doi.org/10.1186/s12906-016-1236-4] [PMID: 27460904]
[http://dx.doi.org/10.5897/AJPP2015.4488] [PMID: 27158431]
[http://dx.doi.org/10.5455/jice.20160904102857] [PMID: 27757273]
[http://dx.doi.org/10.2217/thy.11.19]
[http://dx.doi.org/10.1016/j.neuint.2006.07.004] [PMID: 16959376]
[PMID: 29568187]
[http://dx.doi.org/10.1007/s11064-018-2505-z] [PMID: 29541930]